Teva (NYSE:TEVA) announced today that it has launched a Bluetooth-enabled version of its ProAir albuterol sulfate rescue inhaler.
The ProAir Digihaler’s sensors connect to a companion mobile app to provide inhaler-use information to healthcare providers. The new inhaler is available by prescription to U.S. patients age 4 and older, according to the Tel Aviv, Israel-based company.
The ProAir Digihaler is designed to detect, record and store inhaler event data, including timestamp and inhalation characteristics such as peak inspiratory flow. Patients are then able to view this data on the app, which informs them if their inhaler technique needs improvement. Patients can share these data with their healthcare providers.
Get the full story on our sister site, Drug Delivery Business News